POP BIO awarded $2.84M Phase II SBIR for seasonal influenza vaccine development

EIN Presswire reported that POP Biotechnologies, co-founded by Jonathan Lovell, will collaborate with UB to pursue the development of a unique vaccine approach against seasonal influenza.